Cytotoxic and anti-inflammatory activities of compounds 1–10.
| Cpd | Cytotoxicity, C50ac (μM) | Anti-inflammatory activity, EC50bc (μM) | |
|---|---|---|---|
| DLD-1 | WS-1 | ||
| 1 | 20 ± 3 | 36 ± 1 | 14 ± 1 |
| 2 | 13 ± 2 | 14 ± 2 | 9 ± 1 |
| 3 | 4.0 ± 0.5 | 33 ± 6 | NAd |
| 4 | 5 ± 1 | >100 | NAd |
| 5 | >100 | >100 | NAd |
| 6 | >100 | >100 | NAd |
| 7 | 15 ± 1 | 23 ± 1 | 10.5 ± 0.3 |
| 8 | >100 | 70 ± 4 | 16 ± 3 |
| 9 | >100 | >100 | 9.8 ± 0.3 |
| 10 | >100 | >100 | 11 ± 2 |
| Rha-2-Bet | 2.08 ± 0.03 | 2.5 ± 0.3 | 14 ± 1 |
a
IC50: concentration inhibiting 50% of cell growth. 28-O-α-l-Rhamnopyranosylbetulin 3β-O-α-l-rhamnopyranoside (Rha-2-Bet) was used as positive control.
b
EC50: efficacy concentration inhibiting 50% of NO overproduction induced by LPS. l-NAME was used as positive control inhibits 54% of NO overproduction at 250 μM.
c
The results are the mean ± standard deviation of three determination and are representative of three different experiments.
d
NA: not active; compound was considered inactive when EC50 is ≥50 μM.